

Key Information and Investment Disclosure Statement As of May 31, 2024

FUND FACTS

Classification: Equity Feeder Fund NAVPU: USD 94.77 Launch Date: February 1, 2021 Total Fund NAV (Mn): USD 5.75

USD 100.00 **Minimum Investment: Dealing Day:** Daily up to 2:00 PM **Additional Investment:** No minimum **Redemption Settlement:** T+5 End-of-Day

Minimum Holding Period: None **Early Redemption Charge:** None

FEES

Trustee Fees: 0.1270%* **Custodianship Fee: 0.0000%** External Audit Fee: 0.0000%** Other Fees: 0.0138%***

1.50% per annum

BPI Wealth None Isla Lipana Index Licensing Fee

*Monthly rate: Billings received for May 2024 divided by the average daily NAV for the same month valued at USD 5.80 Mn

**Billing is received at the last guarter of the year

***Billings received in May 2024

INVESTMENT OBJECTIVE AND STRATEGY

The Fund, operating as a Feeder Fund, intends to achieve long term capital growth by investing in a Target Fund that invests in stocks in the health care sector. The Fund aims to provide excess return over the MSCI World Health Care Index. Pursuant to existing BSP rules and regulations, as a Feeder Fund, this Fund is mandated to invest at least 90% of its assets in a single collective investment scheme.

CLIENT SUITABILITY

A client profiling process shall be performed prior to participating in the Fund to guide the prospective investor if the Fund is suited to his/her investment objectives and risk tolerance. Clients are advised to read the Declaration of Trust/Plan Rules of the Fund, which may be obtained from the Trustee, before deciding to invest.

The BPI Global Health Care Feeder Fund is for investors who:

- Are at least classified as aggressive based on their risk profile.
- Have an investment horizon of at least five (5) years.

Participation in the Fund shall be open to Participants with legal capacity to contract and who are not considered US persons under the US securities and tax laws, subject to the other conditions, rules or provisions stated in the Plan Rules and those established by the Trustee. No beneficial owner shall hold more than 10% of the Fund. Any investor who owns more than 10% shall be asked to redeem the amount (or its equivalent number of units) in excess of 10% within thirty (30) calendar days.

KEY RISKS AND RISK MANAGEMENT

You should not invest in this Fund if you do not understand or are not comfortable with the accompanying risks.

Market/Price Risk:

Investors are exposed to adverse changes in the prices of global equities in the health care sector due to adverse market conditions, unfavorable company earnings and valuations, and negative developments in the political and economic conditions of the focus countries of the securities of the target fund.

Investors are exposed to the risk of loss due to the target fund's inability to convert security holdings to cash Liquidity Risk: immediately or in instances where conversion to cash is possible but at a highly disadvantageous price due to

limited participants in the market, low trading volumes, market disruptions, among others.

Country Risk:

Investors are exposed to the risk of loss arising from negative developments in the political, economic and social conditions of the focus countries of the underlying securities of the target fund, which may adversely

affect the value of the feeder fund.

FX Risk:

Investors are exposed to the risk of loss from a decline in the market value of the target fund when the market value of foreign currency denominated securities held by the target fund are translated to USD.

The Fund's investment outlets undergo proper screening and evaluation in accordance with the Trustee's accreditation process. The Fund may also use financial derivatives to hedge the portfolio against market and credit risks.

- THE UIT FUND IS NOT A DEPOSIT AND IS NOT INSURED BY THE PHILIPPINE DEPOSIT INSURANCE CORP. (PDIC).
- RETURNS CANNOT BE GUARANTEED AND HISTORICAL NAVPU IS FOR ILLUSTRATION OF NAVPU MOVEMENTS/ FLUCTUATIONS ONLY.
- WHEN REDEEMING, THE PROCEEDS MAY BE WORTH LESS THAN THE ORIGINAL INVESTMENT AND ANY LOSSES SHALL BE SOLELY FOR THE ACCOUNT OF THE CLIENT.
- THE TRUSTEE IS NOT LIABLE FOR ANY LOSS UNLESS UPON WILLFUL DEFAULT, BAD FAITH OR GROSS **NEGLIGENCE.**
- •THIS PRODUCT CANNOT BE SOLD TO YOU UNLESS ITS BENEFITS AND RISKS HAVE BEEN THOROUGHLY EXPLAINED. IF YOU DO NOT FULLY UNDERSTAND THIS PRODUCT, DO NOT PURCHASE OR INVEST IN IT.

FUND PERFORMANCE AND STATISTICS AS OF MAY 31, 2024

(Purely for reference purposes and is not a guarantee of future results)

NAVPU	GRAPH				
130					400 A
115	mon	1	Ame My	Mary and the	
100	MVV.	Ala. M.	•		M A
85	\W'	JANA MANANA		anna de la companya d	
70	Fund —	Benchmark*			
Apr-21	Dec-21	Jul-22	Mar-23	Oct-23	May-24

85						
	Fund ——E	Benchmark	*		•••	
Apr-21	Dec-21	Jul-22	Mar-2	23 (Oct-23	May-24
•	Health Care Inde	žΧ				,
CUMULATIVE PERFORMANCE (%) 1						
	1 mo	3 mos	6 mos	1YR	3YRS	S.I. ²
Fund	2.38	-0.45	10.52	9.80	-3.27	-5.23
Benchmarl			10.67	12.59	16.76	22.87
ANNUALIZ	ZED PERFOR	RMANCE	(%) ¹			
	1YR	2YRS	3YRS	4YRS	5YR	S.I. ²
Fund	9.80	6.41	-1.10	-	-	-1.60
Benchmarl		5.97	5.30	-	-	6.38
CALENDAR YEAR PERFORMANCE (%) 1						
	YTD	2023		2021 ³		
Fund	3.52	4.37	-11.52	-0.86		
Benchmarl		3.33	-5.02	18.13		
	IO COMPOSI	TION				
Allocation % of Fund						
Target Fund 97.99						
Cash and Equivalents 1.68						
Others – net of liabilities 0.32						
Regional Breakdown % of Target Fund						
United States 71.10						
United Kingdom 7.44						
Denmark 6.39						
Others 15.07						
Sector Breakdown % of Target Fund						
Major Pharmaceuticals 27.16						
Biotechnology 19.46						
Health Services 15.20						
Medical Technology 12.44						

NAVPu over the past 12 months				
Highest	97.45			
Lowest	79.73			
STATISTICS				
Volatility, since inception (%) 4	12.96			
Sharpe Ratio ⁵	0.34			
Information Ratio ⁶	-0.42			
10.1				

- ¹ Returns are net of fees.
- ² Since Inception
- ³ Fund performance from Feb to year-end 2021
- ⁴ Measures the degree to which the Fund fluctuates vis-àvis its average return over a period of time
- ⁵ Used to characterize how well the return of a Fund compensates the investor for the level of risk taken. The higher the number, the better.
- ⁶ Measures reward-to-risk efficiency of the portfolio relative to the benchmark. The higher the number, the higher the reward per unit of risk.

*Declaration of Trust is available upon request through your branch of account.

TOP TEN HOLDINGS

Name	% of Target Fund
Eli Lilly & Co	9.74
UnitedHealth Grp Inc	6.74
Novo Nordisk A/S	5.05
Merck & Co Inc	4.76
AstraZeneca PLC	4.32
Novartis AG	2.81
Danaher Corp	2.77
Bos Scientific Corp	2.59
GSK PLC	2.08
Daiichi Sankyo Co	2.04

RELATED PARTY TRANSACTIONS*

The Fund has no transactions and outstanding investments with entities related to BPI Wealth – A Trust Corporation ("BPI Wealth").

* Related party in accordance with BPI Wealth's internal policy.

OTHER FUND FACTS

Others

Fund Currency: US Dollar **Fund structure:** UCITS (IRL)

Benchmark*: MSCI World Health Care Index **Inception Date:** October 31, 2003

25.74

Wellington Global Health Care Equity State Street Custodial Services Name of Target Fund:

Custodian: (Ireland) Limited

Regulator: Central Bank of Ireland **Total Expense Ratio:** 1.32%

Fund Manager: Wellington Management Company LLP

Fund

The Fund Performance Report and relevant information about the Wellington Global Health Care Equity Fund can be viewed and downloaded through https://www.wellingtonfunds.com/en-at/institutional/.

OUTLOOK AND STRATEGY

Market Review. Global equities rebounded in May after April's pullback, with the MSCI All Country World Index returning 4.1% for the month as investor sentiment improved amid easing inflation concerns. In the US, the S&P 500 returned 5.0% driven by strong corporate earnings despite rate cuts being pushed back to later this year. The Flash PMI indicated further expansion in business activity, with the manufacturing and services PMIs accelerating to 51.3 and 54.8 in May from 50.0 and 51.3 last month. Eurozone equities advanced driven by increase in business activity and an anticipated policy rate cut in June by the European Central Bank. In Japan, the TOPIX returned 1.1%, lagging the broader global index, as the continued weakness of the Yen dampened market sentiment. Emerging market equities were flat for the month, with the MSCI Emerging Market Index returning 0.6%. Returns were supported by China's improving economic data and stimulus and optimism on the Fed's rate cuts but was offset by profit-taking and risk-off sentiment towards the end of the month. The MSCI World Health Care returned 2.7% over the month. Within the index, all of the sectors rose over the month. Biopharma large cap and biopharma mid cap were the top performing sectors, while health care services and medical technology were the bottom performing sectors for the period.

Fund Performance. The fund returned 2.38% in May, lagging the benchmark by 29 basis points. Allocation effect was driven by our underweight to biopharma large cap and out of benchmark allocation to biopharma small cap, but partially offset by our underweight tot medical technology. Strong selection in health care services was partially offset by selection in biopharma mid cap.

Fund Strategy. Groundbreaking innovation, supportive valuations and business models positioned to show resilience through the cycle should benefit the sector over the long-term. Within the biopharma industry, breakthrough innovations continue to provide attractive opportunities. In the US, the fund continues to monitor the next steps in IRA policy implementation, but valuations remain attractive and recent developments continue to support robust growth assumptions for major indications. Outside of biopharma, medical technology companies have numerous opportunities due to advancements in technology development, engineering capabilities and integrated informatics. Recent volatility and disruption across the subsector have created new investment opportunities, particularly across interventional cardiology, life science tools, and diagnostics including (blood) biopsy, where valuations look attractive. Within health care services, the fund favors companies focused on the societal challenge on improving patient outcomes while reining in costs. The fund will continue to favor companies that develop innovative products designed to address important unmet medical needs. Over the long term, the tailwinds of innovation and an aging population should continue to drive growth for the sector.

LIST OF PROSPECTIVE INVESTMENTS

The following are among the Fund's approved investment outlets, wherein the Trustee intends to invest depending on strategy, availability, or other market-driven circumstances:

- (a) Primarily in a single collective investment scheme whose investment objective is to provide investment results in excess of the return of the MSCI World Health Care Index; provided further that such CIS is approved or registered and supervised by a regulatory authority that is a member of the International Organization of Securities Commissions (IOSCO) and managed by reputable fund manager/s; provided further that the investment in the said collective investment scheme should at least be ninety percent (90%) of the total assets of the Fund. The Target Fund must be recognized as a collective investment scheme in its home jurisdiction by a regulatory authority or any regulatory authority acceptable to the BSP to supervise this CIS.
- (b) Short-term tradable fixed-income instruments issued or guaranteed by the Philippine government or the BSP; tradable securities issued by the government of a foreign country, any political subdivision/agency of a foreign country or any supranational entity; tradable fixed-income instruments issued by foreign or local financial institutions or private corporations; exchange- listed securities; marketable instruments that are traded in an organized exchange; loans traded in an organized market; and, such other tradable investments outlets/ categories as the BSP may allow. Provided, that, a financial instrument is regarded as tradable if two-way prices are quoted, readily available or regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis.
- (c) Short-term tradable fixed-income instruments issued, underwritten, or otherwise dealt by BPI and/or any of its subsidiaries, affiliates, their successors-in-interest or assignees, their directors, officers, stockholders, and related interest, and any of their trust and fund managed accounts, under such terms and conditions as the Trustee may deem to be in the best interest of the Fund; and, any such other instruments as may be allowed under BSP regulations. Investment with related interests shall be in accordance with Section 414-Q of the Manual of Regulations for Non-Bank Financial Institutions.
- (d) The principal investments of the Fund will be denominated in, but not limited to the U.S. Dollar. The target fund invests in securities denominated in other currencies.
- (e) Bank deposits or tradable debt instruments issued by the BSP.
- (f) Such other investments allowed under regulations issued by the BSP.

INVESTMENT OBJECTIVE OF TARGET FUND

The Wellington Global Health Care Equity Fund seeks long-term total returns. The Investment Manager will actively manage the Fund, seeking to achieve the objective by investing in the equity securities of health care companies worldwide. The Fund takes a long term value approach and seeks to invest in fundamentally sound companies. Although the Fund is not constructed relative to a benchmark, the MSCI World Health Care index will serve as a reference benchmark.

BPI Wealth is a subsidiary of the Bank of the Philippine Islands. For inquiries and comments, please send an email to bpiwealth@bpi.com.ph or call us at (632) 8580-2682.

BPI Wealth as Trustee/Investment Manager is regulated by the Bangko Sentral ng Pilipinas. https://www.bsp.gov.ph